Identification of candidate genes with pro-apoptotic properties by functional screening of randomly fragmented cDNA

M Hassan1, C Matuschek, P A Gerber

  • 1Clinic of Dermatology, University Hospital of Düsseldorf, Germany. dr.hassan@gmx.de

Insights

Researchers developed a new method to identify genes that help tumor cells resist apoptosis. This modified technical knockout strategy can help find new cancer therapies by targeting pro-apoptotic genes.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Tumor cells' resistance to apoptosis impacts cancer treatment efficacy.
  • The CD95-signaling pathway is crucial in apoptosis, but tumor cells often resist its effects.
  • Identifying genes that regulate this resistance is vital for developing new therapies.

Purpose of the Study:

  • To develop a rapid and efficient method for identifying functional genes involved in CD95-mediated apoptosis resistance in tumor cells.
  • To overcome the limitations of conventional technical knockout (TKO) strategies for gene identification.

Main Methods:

  • Modified a conventional technical knockout (TKO) strategy using transiently expressed cDNA libraries with multi-cycle selection.
  • Replaced stable expression of randomly fragmented cDNA with a multi-cycle selection procedure.
  • Introduced identified antisense mRNA molecules into tumor cells to validate their function.

Main Results:

  • Successfully identified a small number of antisense mRNA molecules that block pro-apoptotic gene function.
  • The modified TKO strategy demonstrated rapid and significant identification of relevant genes.
  • Re-introduction of identified antisense mRNA confirmed their ability to inhibit pro-apoptotic gene function in various tumor types.

Conclusions:

  • The modified TKO strategy is a generally applicable procedure for identifying functional genes.
  • This method can identify genes with pro-apoptotic properties relevant to tumor therapy.
  • The findings offer potential new targets for enhancing cancer treatment efficacy.